Ropivacaine is named as an intervention in 8 current clinical trials in our China and USA registers. 5 are recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is Huazhong University of Science and Technology (2). The most-studied condition is Postsurgical Pain Management.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Effect of Dexmedetomidine Combined With FNB/ACB on Sleep Quality After Knee Surgery
NCT07767383 · ClinicalTrials.gov ↗ · Knee Arthroscopic Surgery
|
Phase 4 | Recruiting | Affiliated Hospital of Nantong University | China |
|
A Study on TLC590 for Managing Postsurgical Pain
NCT06574269 · ClinicalTrials.gov ↗ · Postsurgical Pain Management
|
Phase 2 | Recruiting | TLC Biopharmaceuticals, Inc. | USA |
|
Efficacy and Safety of Cocktail of Ropivacaine for Local Infiltration Analgesia in Patients Undergoing Laparoscopic Cholecystectomy
NCT06819748 · ClinicalTrials.gov ↗ · Cholecystectomy, Laparoscopic, Ambulatory Surgical Procedures, Multimodal Analgesia
|
Not applicable | Recruiting | Sichuan Provincial People's Hospital | China |
|
Pre-emptive Scalp Infiltration With Low-dose Flurbiprofen and Ropivacaine for Postoperative Analgesia After Craniotomy
NCT07209345 · ClinicalTrials.gov ↗ · Post-craniotomy, Pain
|
Not applicable | Recruiting | Beijing Tiantan Hospital | China |
|
QLESP Block Versus PENG+LFCN Block for Total Hip Arthroplasty
NCT07771829 · ClinicalTrials.gov ↗ · Pain Management, Arthroplasty Total Hip Replacement
|
Not applicable | Recruiting | Huazhong University of Science and Technology | China |
|
QLESP Block for Pain Control in Robotic Partial Nephrectomy
NCT07704970 · Renal Cell Carcinoma (Kidney Cancer), Postoperative Pain, Nerve Block
|
Not applicable | Not yet open | Huazhong University of Science and Technology | China |
|
Exploring the Minimum Effective Concentration and Volume of Ropivacaine for Sacral Plexus Anesthesia
NCT06711679 · ClinicalTrials.gov ↗ · Pediatric ALL
|
Phase 4 | By invitation | Yilin Zhao | China |
|
Anesthetic Effect of Ropivacaine on Local Infiltration Anesthesia in Arteriovenous Fistula Surgery
NCT07259772 · ClinicalTrials.gov ↗ · End Stage Renal Disease (ESRD), Arteriovenous Fistula Patency, Chronic Kidney Disease 5D
|
Phase 4 | Active, closed | The First People's Hospital of Lianyungang | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
4 single-substance products containing Ropivacaine on the HPRA medicines list.
| Condition (as registered) | Trials |
|---|---|
| Postsurgical Pain Management | 1 |
| Renal Cell Carcinoma (Kidney Cancer) | 1 |
| Postoperative Pain | 1 |
| Nerve Block | 1 |
| Knee Arthroscopic Surgery | 1 |
| Post-craniotomy | 1 |
| Pain | 1 |
| Pain Management | 1 |
| Arthroplasty Total Hip Replacement | 1 |
| End Stage Renal Disease (ESRD) | 1 |
| Arteriovenous Fistula Patency | 1 |
| Chronic Kidney Disease 5D | 1 |
| Pediatric ALL | 1 |
| Cholecystectomy, Laparoscopic | 1 |
| Ambulatory Surgical Procedures | 1 |
| Multimodal Analgesia | 1 |
| Lead sponsor | Trials |
|---|---|
| Huazhong University of Science and Technology | 2 |
| TLC Biopharmaceuticals, Inc. | 1 |
| Affiliated Hospital of Nantong University | 1 |
| Beijing Tiantan Hospital | 1 |
| The First People's Hospital of Lianyungang | 1 |
| Yilin Zhao | 1 |
| Sichuan Provincial People's Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 7 | 4 |
| Clinical trials in USA | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
8 current trials in our China and USA registers name Ropivacaine as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 5 of the 8 trials are recruiting: 4 with sites in China and 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Huazhong University of Science and Technology (2), TLC Biopharmaceuticals, Inc (1), Affiliated Hospital of Nantong University (1) and Beijing Tiantan Hospital (1), among 7 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 4 single-substance products containing Ropivacaine, for example Naropin 7.5 mg/ml solution for injection (Rowex Limited,). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
The registers we track list 4 entries for Ropivacaine: US FDA: current; 3 German notices. Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Ropivacaine works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Ropivacaine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ropivacaine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.